VTRS
Viatris Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$16.88
−0.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 14.7B | 14.3B | 14.7B | 15.4B | 16.3B |
| Cost of Revenue | 9.6B | 9.3B | 9.1B | 9.0B | 9.8B |
| Gross Profit | 5.1B | 5.0B | 5.6B | 6.4B | 6.5B |
| Operating Expenses | |||||
| R&D Expense | 1.0B | 965.9M | 808.7M | 805.2M | 662.2M |
| SG&A Expense | 4.0B | 3.8B | 4.4B | 4.7B | 4.2B |
| General & Admin Expense | 1.1B | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 221.5M | 2.9B | 379.2M | 217.1M | 40.8M |
| Total Operating Expenses | 5.2B | 7.7B | 5.6B | 5.7B | 4.9B |
| Cost and Expenses | 14.8B | 17.0B | 14.7B | 14.7B | 14.6B |
| Operating Income (EBIT) | (87.3M) | (2.7B) | 10.1M | 766.2M | 1.6B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 480.0M | 471.3M | 550.0M | 573.1M | 592.4M |
| Net Interest Income | (480.0M) | (471.3M) | (550.0M) | (573.1M) | (592.4M) |
| Other Non-Op Income/Expense | (574.9M) | (1.0B) | (633.3M) | (563.3M) | 1.2B |
| Non-Operating Income (excl Interest) | (100.0K) | 530.6M | 83.3M | (9.8M) | (1.8B) |
| EBT (Pre-Tax Income) | (662.2M) | (3.7B) | (623.2M) | 202.9M | 2.8B |
| Income Tax Expense | (251.5M) | (150.1M) | 11.0M | 148.2M | 734.6M |
| Bottom Line | |||||
| Net Income | (410.7M) | (3.5B) | (634.2M) | 54.7M | 2.1B |
| Earnings from Cont. Ops | (410.7M) | (3.5B) | (634.2M) | 54.7M | 2.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (410.7M) | (3.5B) | (634.2M) | 54.7M | 2.1B |
| Per Share | |||||
| Basic EPS | ($0.36) | ($3.00) | ($0.53) | $0.05 | $1.71 |
| Diluted EPS | ($0.36) | ($3.00) | ($0.53) | $0.05 | $1.71 |
| Revenue Per Share | $12.67 | $12.21 | $12.35 | $12.85 | $13.42 |
| Shares | |||||
| Basic Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B |
| Diluted Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B |
| Profitability Metrics | |||||
| EBITDA | 2.6B | (395.4M) | 2.8B | 3.5B | 6.4B |
| D&A | 2.7B | 2.8B | 2.9B | 2.7B | 3.0B |
| EBIT | (87.2M) | (3.2B) | (73.2M) | 776.0M | 3.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026